Oxaliplatin in Cancer Patients With Impaired Kidney Function
Status:
Completed
Trial end date:
2001-12-01
Target enrollment:
Participant gender:
Summary
Oxaliplatin is an experimental anti-cancer drug that can shrink tumors such as colon cancer.
However, because this drug can damage the kidneys, it is necessary to determine what doses of
the drug can safely be given to patients with poor kidney function.
Patients with advanced cancer, poorly functioning kidneys, and no good standard treatment
options are eligible for this study. Candidates will be screened with imaging tests, such as
CT and MRI scans, to determine the size and location of the cancer and with blood and urine
tests to evaluate kidney and liver function.
Study participants will receive oxaliplatin intravenously (through a vein) every 3 weeks for
as long as the cancer is under control and there are no serious side effects from the drug.
If significant side effects develop, the dosage will be reduced, or the drug will be stopped.
Blood tests to measure blood cell counts will be done at least once a week, and CT scans,
chest X-rays, and MRIs will be done about once every 6 weeks to assess the tumor's response
to the treatment. Additional blood tests will be done at the beginning of the first two
treatment cycles to measure the amount of oxaliplatin in the blood, and urine will be
collected during the first 24 hours of drug treatment to determine how much drug is
eliminated by the body in urine.